Abstract: The invention relates to the field of flow cytometry and more particularly to a panel of antibody reagents conjugated to fluorescent compounds. Provided are reagent compositions, comprising at least eight distinct fluorochrome-conjugated antibodies comprising a set of at least three identification antibodies for the identification of a leukocyte population of interest and at least four characterization antibodies for further characterization and/or classification of said leukocyte population. Also provided are kits and methods related to the reagent compositions.

Abstract: This invention relates to the field of primary immunodeficiencies (PID), more specifically to means and method for the diagnosis of PID of the lymphoid system. Provided are unique reagent compositions for the flow cytometric immunophenotyping of leukocytes comprising fluorochrome-conjugated antibodies directed against various specific combinations of markers. Also provided are kits comprising the reagent compositions, and methods using the same.

Abstract: The invention relates to methods to evaluate in one single assay the biocompatibility of materials based on the simultaneous determination of the phagocytosis, cell activation and cell death produced by said materials, preferably, in peripheral blood or other human cells and proximal fluids. The invention also relates to a kit to perform the method of the invention.

Abstract: The invention relates to the field of medical diagnostics. In particular, it relates method and kits for identification and classification of IgE-related diseases, e.g. Type I hypersensitivity, as well as for monitoring of treatment efficacy, for instance anti-IgE therapy.

Abstract: This invention relates to methods to detect the presence of cancer infiltration of the Central Nervous System (CNS) based on the detection of soluble proteins, preferably, in cerebrospinal fluid samples and vitreous fluid. The invention also relates to kits to perform the methods of the invention.

Abstract: The invention relates to the field of minimal residual disease (MRD) diagnostics, which is progressively more applied for the evaluation of treatment effectiveness in patients with a hematological malignancy, such as B-cell precursor acute lymphoblastic leukemia (BCP-ALL), B-cell chronic lymphocytic leukemia (B-CLL), and multiple myeloma (MM). Provided are unique reagent compositions with carefully selected and thoroughly tested combinations of antibodies, for ?8-color flow cytometric stainings as well as for 10-color and 12-color flow cytometric stainings, which can reach sensitivities of at least 10?4, even down to 10?5. Also provided are diagnostic kits and methods for detecting MRD.

Abstract: The invention relates to the field of medical diagnostics. In particular, it relates method and kits for identification and classification of IgE-related diseases, e.g. Type I hypersensitivity, as well as for monitoring of treatment efficacy, for instance anti-IgE therapy.

Abstract: The invention relates to the field of medical diagnostics. Provided are methods and kits for determining the health status of a subject, for early detection of tissue damage, for early diagnosis and monitoring of a disease, and/or for evaluation of treatment effectiveness in a subject using circulating tissue macrophages (CTM) as a mirror of disrupted tissue homeostasis and disease.

Abstract: This invention relates to methods to detect the presence of cancer infiltration of the Central Nervous System (CNS) based on the detection of soluble proteins, preferably, in cerebrospinal fluid samples and vitreous fluid. The invention also relates to kits to perform the methods of the invention.

Abstract: The invention relates to the field of flow cytometry and more particularly to a panel of antibody reagents conjugated to fluorescent compounds. Provided are reagent compositions, comprising at least eight distinct fluorochrome-conjugated antibodies comprising a set of at least three identification antibodies for the identification of a leukocyte population of interest and at least four characterization antibodies for further characterization and/or classification of said leukocyte population. Also provided are kits and methods related to the reagent compositions.

Abstract: This invention relates to the detection of among others tumor-specific fusion proteins and protein interactions. Provided is a set of at least a first and a second molecular probe, each probe provided with a dye wherein said dyes together allow energy transfer, each probe additionally provided with a reactive group allowing juxtaposing said at least first and second probe, wherein said reactive group is an oligonucleotide and wherein the reactive group of said first probe is not directly reactive with the reactive group of said second probe.

Abstract: Method for the detection of cancerous cells, in particular, mesenchymal tumoral cells, in a biological sample suspected of containing said malignant cells. The methods are based on the aberrant expression of the Slug gene or transcription or expression products thereof. Also disclosed are methods of treatment that based on the alteration of the transcription or expression of the Slug gene and methods for screening the compounds that have cancer treating activities. Pharmaceutical compositions comprising the anti-cancer compounds are also disclosed.

Abstract: A method for detecting aberrant phenotypes expressed by neoplastic cells includes the steps of: 1) staining one or more normal/reactive samples and one neoplastic sample with multiple combinations of monoclonal antibodies, 2) measuring fluorescence emissions associated to the stained cells, 3) storing two independent list mode data files of information on light scatter and fluorescence characteristics of each cell, 4) creating new data files by mixing list mode data from the data file containing information the neoplastic sample into the data file containing information on the normal samples, 5) defining corresponding to normal cells and areas corresponding to empty spaces in normal/reactive samples that may be occupied by tumor cells in neoplastic samples, 6) identifying events corresponding to neoplastic cells and events corresponding to normal cells coexisting in a multidimensional space, and 7) establishing the most relevant phenotypic aberrations displayed by the neoplastic cells as compared to their nor

Abstract: A single measurement can quantify phosphatidyl-inositol glycan complementation class A (PIG-A) associated proteins in red cells, platelets and the major leukocyte subsets present in blood (lymphocytes, monocytes, neutrophils and eosinophils). The single measurement relies on flow cytometry to simultaneously evaluate intensity of fluorochrome emissions and light scattering properties.

Abstract: This invention relates to an improved procedure for the multiparameter analysis of leukocyte subpopulations from peripheral blood, bone marrow or any body fluid containing blood nucleated cells, including the quantification of each subpopulation in terms of cells per microliter. The method uses a cocktail of at least four monoclonal antibodies labelled each with a different fluorescent tag, the measurement of at least two light scatter and four fluorescence emissions related parameters and at least one population of fluorescent beads to differentiate and enumerate between and among the different leukocyte subpopulations in the peripheral blood, the bone marrow or other body fluid.

Abstract: A method that generates new flow cytometry data files with a potentially infinite number of dimensions is described. First two or more separate flow cytometry data files containing information about events measured in different aliquots from the same sample are fused. Then, the magnitude of the values and a corresponding uncertainty measure of the differing variables between one or more of the original data files which have been fused are estimated, for each individual event contained in the fused data file, for which that variable was not directly measured in the flow cytometer. The new data file containing both data actually measured in the flow cytometer for each event of the individual original data files fused and the estimated data for those parameters not measured in a group of events from one or more of the original data files are reconstructed multidimensionally.

Abstract: Method for the detection of cancerous cells, in particular, mesenchymal tumoral cells, in a biological sample suspected of containing said malignant cells. The methods are based on the aberrant expression of the Slug gene or transcription or expression products thereof. Also disclosed are methods of treatment that based on the alteration of the transcription or expression of the Slug gene and methods for screening the compounds that have cancer treating activities. Pharmaceutical compositions comprising the anti-cancer compounds are also disclosed.

Abstract: Procedure for controlling the enumeration of the absolute count of cells (or other particles) present in a sample.

Abstract: A new method for detecting aberrant phenotypes expressed by neoplastic cells present in bone marrow, peripheral blood, spinal fluid and lymph nodes, comprising the steps of: 1) separately staining one or more normal/reactive samples and one neoplastic sample with identical or partially overlapping, multiple combinations of monoclonal antibodies, 2) sequentially measuring the fluorescence emissions associated to large numbers of cells stained with the monoclonal antibodies from the normal/reactive samples and the neoplastic sample, 3) storing two independent list mode data files each containing information on the specific light scatter and fluorescence characteristics of each cell analyzed, 4) creating new data files by mixing list mode data from the data file containing information about the cells present in the neoplastic sample into the data file containing information on the cells present in the normal samples, 5) defining those areas occupied by events corresponding to normal cells and those areas corresp

Abstract: This invention relates to an improved procedure for the multiparameter analysis of leukocyte subpopulations from peripheral blood, bone marrow or any body fluid containing blood nucleated cells, including the quantification of each subpopulation in terms of cells per microliter. The method uses a cocktail of at least four monoclonal antibodies labelled each with a different fluorescent tag, the measurement of at least two light scatter and four fluorescence emissions related parameters and at least one population of fluorescent beads to differentiate and enumerate between and among the different leukocyte subpopulations in the peripheral blood, the bone marrow or other body fluid.